{"id":"vargatef","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01484080","NCT07332117","NCT02452463","NCT05635071","NCT02182206","NCT03675581","NCT05676112","NCT05779007","NCT01024920","NCT04939467","NCT00876460","NCT01770392","NCT02607722","NCT01349296","NCT00904839","NCT05065190","NCT01335477","NCT06650774","NCT05817240","NCT02665143","NCT01658462","NCT03939520","NCT02149108","NCT03725852","NCT02751385","NCT01610869","NCT02182050","NCT01441297","NCT05195918","NCT06297096","NCT01695408","NCT04541680","NCT04856111","NCT04419506","NCT02619162","NCT02802345","NCT00805194","NCT02182141","NCT05755308","NCT01136174","NCT04888715","NCT03502902","NCT02308553","NCT04046614","NCT00710762","NCT05870956","NCT02597933","NCT05022784","NCT00715403","NCT01619085"],"aliases":["Nintedanib","L01xe31"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"vargatef","companyId":"arcagy-gineco-group","ecosystem":[],"mechanism":{"target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"ARCAGY/ GINECO GROUP","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"vargatef","indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis","diseaseId":"idiopathic-pulmonary-fibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Interstitial fibrosis","diseaseId":"interstitial-fibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-small cell lung cancer","diseaseId":"non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic sclerosis associated interstitial lung disease","diseaseId":"systemic-sclerosis-associated-interstitial-lung-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01484080","phase":"Phase 1","title":"Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging C","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","isPivotal":false,"enrollment":140,"indication":"Breast Cancer","completionDate":"2014-04"},{"nctId":"NCT07332117","phase":"N/A","title":"A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","isPivotal":false,"enrollment":30,"indication":"Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis","completionDate":"2026-04"},{"nctId":"NCT02452463","phase":"Phase 2","title":"A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradi","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","isPivotal":false,"enrollment":8,"indication":"Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis","completionDate":"2019-06-10"},{"nctId":"NCT05635071","phase":"Phase 2","title":"Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","isPivotal":true,"enrollment":90,"indication":"Uterine Adhesions","completionDate":"2024-12-30"},{"nctId":"NCT02182206","phase":"Phase 1","title":"A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":50,"indication":"Tumors","completionDate":""},{"nctId":"NCT03675581","phase":"Phase 1","title":"A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstiti","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":17,"indication":"Scleroderma, Systemic","completionDate":"2019-10-10"},{"nctId":"NCT05676112","phase":"N/A","title":"Safety of Nintedanib in Real World in China: a Non-interventional Study Based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study (PORTRAY) Data","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":0,"indication":"Pulmonary Fibrosis","completionDate":"2026-09-30"},{"nctId":"NCT05779007","phase":"N/A","title":"Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":2778,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2023-07-14"},{"nctId":"NCT01024920","phase":"Phase 2","title":"A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":99,"indication":"Carcinoma, Renal Cell","completionDate":"2020-06-19"},{"nctId":"NCT04939467","phase":"Phase 1","title":"A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers","status":"COMPLETED","sponsor":"Blade Therapeutics","isPivotal":false,"enrollment":86,"indication":"Drug Drug Interaction","completionDate":"2022-04-01"},{"nctId":"NCT00876460","phase":"Phase 1","title":"A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cel","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":43,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2015-07"},{"nctId":"NCT01770392","phase":"Phase 1","title":"Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2013-03"},{"nctId":"NCT02607722","phase":"N/A","title":"The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":10117,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2023-05-02"},{"nctId":"NCT01349296","phase":"Phase 1","title":"BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) ","status":"COMPLETED","sponsor":"University of Cologne","isPivotal":false,"enrollment":18,"indication":"Solid Tumors","completionDate":"2016-05"},{"nctId":"NCT00904839","phase":"Phase 2","title":"A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":128,"indication":"Colorectal Neoplasms","completionDate":"2012-01"},{"nctId":"NCT05065190","phase":"Phase 3","title":"A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":81,"indication":"Lung Diseases, Interstitial","completionDate":"2024-05-07"},{"nctId":"NCT01335477","phase":"Phase 3","title":"A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmona","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":551,"indication":"Pulmonary Fibrosis","completionDate":"2013-10"},{"nctId":"NCT06650774","phase":"N/A","title":"Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findingsin Patients With Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Karadeniz Technical University","isPivotal":false,"enrollment":152,"indication":"Idiopathic Pulmonary Fibrosis (IPF)","completionDate":"2024-09-30"},{"nctId":"NCT05817240","phase":"Phase 1","title":"A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects","status":"COMPLETED","sponsor":"Endeavor Biomedicines, Inc.","isPivotal":false,"enrollment":21,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2023-06-21"},{"nctId":"NCT02665143","phase":"Phase 2","title":"A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Yale University","isPivotal":false,"enrollment":25,"indication":"Relapsed/Refractory Acute Myeloid Leukemia","completionDate":"2021-03-30"},{"nctId":"NCT01658462","phase":"Phase 2","title":"A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Canc","status":"COMPLETED","sponsor":"Centre Oscar Lambret","isPivotal":false,"enrollment":51,"indication":"Breast Cancer","completionDate":"2017-10-30"},{"nctId":"NCT03939520","phase":"Phase 4","title":"Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":279,"indication":"Progressive Idiopathic Pulmonary Fibrosis","completionDate":"2026-01-09"},{"nctId":"NCT02149108","phase":"Phase 3","title":"A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standar","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":768,"indication":"Colorectal Neoplasms","completionDate":"2016-08-25"},{"nctId":"NCT03725852","phase":"Phase 2","title":"A Phase II Randomized, Double-blind, Placebo-controlled, 26-week Study to Evaluate the Efficacy, Safety and Tolerability of GLPG1205 in Subjects With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Galapagos NV","isPivotal":false,"enrollment":68,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2020-08-14"},{"nctId":"NCT02751385","phase":"Phase 1","title":"A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":2,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2017-11-28"},{"nctId":"NCT01610869","phase":"Phase 2","title":"Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"University College, London","isPivotal":false,"enrollment":117,"indication":"Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2018-01-11"},{"nctId":"NCT02182050","phase":"Phase 2","title":"A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-smal","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":73,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":""},{"nctId":"NCT01441297","phase":"Phase 2","title":"A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ji-youn Han","isPivotal":false,"enrollment":24,"indication":"Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent","completionDate":"2016-03-31"},{"nctId":"NCT05195918","phase":"Phase 1","title":"Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","isPivotal":false,"enrollment":50,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2026-04-21"},{"nctId":"NCT06297096","phase":"Phase 3","title":"Multicentre Clinical Trial Evaluating the Safety and Efficacy of the Combination of Nintedanib+Tocilizumab Compared to Standard Treatment in Patients With Systemic Sclerosis and Interstitial Lung Dise","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","isPivotal":true,"enrollment":86,"indication":"Systemic Sclerosis, Interstitial Lung Disease","completionDate":"2028-03-30"},{"nctId":"NCT01695408","phase":"N/A","title":"Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.","status":"COMPLETED","sponsor":"Technische Universität Dresden","isPivotal":false,"enrollment":1232,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2021-12-31"},{"nctId":"NCT04541680","phase":"Phase 3","title":"\"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis\"","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":true,"enrollment":250,"indication":"SARS-Cov-2 Induced Pulmonary Fibrosis","completionDate":"2024-07"},{"nctId":"NCT04856111","phase":"Phase 4","title":"A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","isPivotal":false,"enrollment":48,"indication":"Novel Coronavirus-induced Lung Fibrosis","completionDate":"2022-11-30"},{"nctId":"NCT04419506","phase":"Phase 2","title":"A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":147,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2021-10-15"},{"nctId":"NCT02619162","phase":"Phase 1","title":"Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","isPivotal":false,"enrollment":25,"indication":"Breast Cancer","completionDate":"2018-06"},{"nctId":"NCT02802345","phase":"Phase 3","title":"INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alo","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":274,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2018-04-13"},{"nctId":"NCT00805194","phase":"Phase 3","title":"Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in P","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":1314,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2017-11-13"},{"nctId":"NCT02182141","phase":"Phase 1","title":"An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Bene","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":17,"indication":"Multiple Myeloma","completionDate":""},{"nctId":"NCT05755308","phase":"NA","title":"Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","isPivotal":false,"enrollment":114,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2026-04"},{"nctId":"NCT01136174","phase":"Phase 2","title":"A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), a","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":50,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":""},{"nctId":"NCT04888715","phase":"Phase 1","title":"An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between \"DWN12088\" and \"Pirfenidone\" or \"Nintedanib\" in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","isPivotal":false,"enrollment":48,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2021-08-18"},{"nctId":"NCT03502902","phase":"Phase 1","title":"A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","isPivotal":false,"enrollment":55,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2019-03-15"},{"nctId":"NCT02308553","phase":"Phase 1","title":"Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients ","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","isPivotal":false,"enrollment":33,"indication":"Cutaneous Malignant Melanoma","completionDate":"2019-11"},{"nctId":"NCT04046614","phase":"Phase 1","title":"Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology - An AIO Phase Ib Trial","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","isPivotal":false,"enrollment":56,"indication":"Adenocarcinoma of the Lung","completionDate":"2023-09-15"},{"nctId":"NCT00710762","phase":"Phase 2","title":"A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":89,"indication":"Ovarian Neoplasms","completionDate":"2014-03"},{"nctId":"NCT05870956","phase":"N/A","title":"Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":1798,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2023-06-30"},{"nctId":"NCT02597933","phase":"Phase 3","title":"A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung ","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":580,"indication":"Scleroderma, Systemic","completionDate":"2018-11-28"},{"nctId":"NCT05022784","phase":"N/A","title":"Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":1798,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2021-12-30"},{"nctId":"NCT00715403","phase":"Phase 1","title":"Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":41,"indication":"Neoplasms","completionDate":""},{"nctId":"NCT01619085","phase":"Phase 3","title":"An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":true,"enrollment":752,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2021-02-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":14,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}